Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Arvinas, Inc. (ARVN : NSDQ)
 
 • Company Description   
Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

Number of Employees: 280

 
 • Price / Volume Information   
Yesterday's Closing Price: $44.07 Daily Weekly Monthly
20 Day Moving Average: 642,833 shares
Shares Outstanding: 53.17 (millions)
Market Capitalization: $2,343.02 (millions)
Beta: 2.05
52 Week High: $108.47
52 Week Low: $37.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.28% -22.60%
12 Week -33.56% -26.95%
Year To Date -46.35% -34.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5 SCIENCE PARK 395 WINCHESTER AVE
-
NEW HAVEN,CT 06511
USA
ph: 203-535-1456
fax: -
ir@arvinas.com http://www.arvinas.com
 
 • General Corporate Information   
Officers
John Houston - President; Chief Executive Officer and Director
Timothy Shannon - Chairman
Sean Cassidy - Chief Financial Officer
Linda Bain - Director
Wendy Dixon - Director

Peer Information
Arvinas, Inc. (CORR.)
Arvinas, Inc. (RSPI)
Arvinas, Inc. (CGXP)
Arvinas, Inc. (BGEN)
Arvinas, Inc. (GTBP)
Arvinas, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04335A105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 53.17
Most Recent Split Date: (:1)
Beta: 2.05
Market Capitalization: $2,343.02 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.02 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.52 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.24
Price/Cash Flow: -
Price / Sales: 35.87
EPS Growth
vs. Year Ago Period: -42.86%
vs. Previous Quarter: -20.00%
Sales Growth
vs. Year Ago Period: 336.90%
vs. Previous Quarter: -7.98%
ROE
03/31/22 - -29.38
12/31/21 - -27.31
09/30/21 - -27.02
ROA
03/31/22 - -16.05
12/31/21 - -16.93
09/30/21 - -19.69
Current Ratio
03/31/22 - 6.12
12/31/21 - 5.93
09/30/21 - 8.64
Quick Ratio
03/31/22 - 6.12
12/31/21 - 5.93
09/30/21 - 8.64
Operating Margin
03/31/22 - -326.72
12/31/21 - -409.29
09/30/21 - -794.97
Net Margin
03/31/22 - -326.72
12/31/21 - -409.29
09/30/21 - -794.97
Pre-Tax Margin
03/31/22 - -319.77
12/31/21 - -408.99
09/30/21 - -794.98
Book Value
03/31/22 - 13.60
12/31/21 - 14.78
09/30/21 - 16.62
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.14
12/31/21 - 0.13
09/30/21 - 0.12
 

Powered by Zacks Investment Research ©